Instructions for Atoris (Atorvastatin) pills
Description:
Pills covered with white film wraps, round, slightly double-bulged; On the fracture is a white mass with a rough surface.
1 tab
calcium atorvastatin 10.36 mg,
which corresponds to the content of Atorvastatin 10 mg
Auxiliary substances: Powidon - 5.8 mg, sodium lauryl sulfate - 2.9 mg, calcium carbonate - 31.84 mg, cellulose micro crystalline - 29 mg, lactose monohydrate - 57 .125 mg, sodium cross-carmellosis - 7.25 mg, Stearat magnesium - 725 ug.
Shell composition: Opadra II HP 85F28751 white (polyvinyl alcohol, titanium dioxide (E171), macrogol 3000, talk) - 4.35 mg.
10 pcs. - Blister (3) - cardboard packs.
10 pcs. - Blister (9) - cardboard packs.
ATX codes
C10AA05 Atorvastatin
Pharmacological groups / Group membership:
Hypolypidemic drug Atoris
Active substance
Atorvastatin
Pharmacy Group:
Hypolypdydydydym - inhibitor of GMG-COA redictase
Pharmaceuticals:
Hypolypdemic remedy from statin group. Based on the principle of competitive antagonism, the static molecule is linked to that part of the Cohenzim A receptor, where the GMG-COA-reduktase is attached. Another part of the statin molecule ingibifies the process of turning hydroxymethylglutarate into mevalonate, an intermediate product in the synthesis of the cholesterol molecule. The inhibitation of activity of GMG-COA-reduktase leads to a series of successive reactions, resulting in the reduction of intracellular cholesterol content and compensatory increase of activity of LNP-receptors and, accordingly, acceleration of catabolysis of chesterine (.) PPP.
The hypopolypdemic effect of statins is associated with the decrease in the level of total Hs due to Hs-LPNP. The reduction of the LNP level is dose-dependent and is not linear but exponential. The inhaling effect of Atorvastatin on GMG-COA-reduktase is approximately 70% determined by the activity of its circulating metabolites.
Statins do not affect lipoprotein and hepatic lipas activity, have no significant effect on the synthesis and catabolism of free fatty acids, so their effect on the TG level is secondary and mediated through their main effects on the reduction of the XS-LNP level. The moderate decrease in the level of TG for treatment with statins appears to be due to the expression of statin (Apo E) receptors on the surface of hepatocytes involved in the catabolism of the STD, which comprise approximately 30% of the TG. Compared to other statins (except rozuwastatin), Atorvastatin causes a more pronounced decrease in the TG level.
In addition to the hypolipidemic effect, statins have a positive influence on the dysfunction of endothelium (pre-clinical sign of early atherosclerosis), on the vascular wall, the condition of the atheroma, improve the blood's reological properties, antioxididid, proliferative properties.
Atorvastatin reduces cholesterol in patients with homozygous family hypercholestery, which is usually not suitable for the therapy of hypolypy
Testimonials:
- Primary hypercholesteryemia (heterozygous family and non-family hypercholesteryemia (type IIa according to Fredrikson's classification);
- combined (mixed) hyperlipidemic (types IIa and IIb of Fredrikson's classification);
- disbetalypoproteinemia (type III by Fredrikson's classification) (as a supplement to diet)
- family endogenous hypertriglyceridedia (type IV in Fredrikson's classification), resistant to diet;
- Homosigotic family hypercholesteryemia with insufficient efficiency of dietotherapy and other nepharmacological treatments.
- Primary prevention of cardiovascular complications in patients without clinical signs of IVS, but having several risk factors of its development - age over 55 years, nicotine dependence, arterial hypertension, diabetes mellitus, low concentrations of HC-LPV in plastics Blood snake, genetic predisposition, including against the
- background of the dyslipdemia.
- Secondary prevention of cardiovascular complications in patients with IVS in order to reduce the total mortality rate, myocardial heart attack, stroke, re-hospitalization for stenocardia and the need for re-uscularization.
Method of application, course and dosage:
The treatment takes place against the background of a standard diet for patients with hypercholesteryemia. The dose is set individually, depending on the initial level of cholesterol. Accepted inside. The initial dose is usually 10 mg 1 time per day. The effect occurs within 2 weeks and the maximum effect is within 4 weeks. If necessary, the dose can be gradually increased at intervals of 4 weeks or more. Maximum daily dose - 80 mg.
Drug Interaction:
At the same time, the concentration of digoxin in the blood plasma is slightly increased with the use of a digoxin-based Atorvastatin.
Diltiazem, verapamyl, isradipine ingibate isoferment CYP3A4, which is involved in the metabolism of Atorvastatin, so if simultaneously used with these calcium channel blockers it is possible to increase the concentration of atorvastatiatiatiin plasin plasm blood and increased risk of myopathy.
When simultaneously using itraconazol, the concentration of atrvastatin in the blood plasma is significantly increased, apparently due to the inhibition by itraconazole of its metabolism in the liver, which occurs with the participation of the isofferm CYP3A4; increased risk of myopathy.
If the colostipol is applied simultaneously, it is possible to reduce the concentration of Atorvastatin in the blood plasma, and the hypolypidemic effect is increased.
At the same time, anthacids containing magnesium hydroxide and aluminum hydroxide reduce the concentration of Atorvastatin by about 35%.
When simultaneously using cyclosporine, fibros (including hemfibrozyl), antifungal drugs Atoris of derivative azol, nicotine acid increase the risk of development of
myopathy.
When simultaneously using erythromycin, claritromycin, the concentration of Atorvastatin in plasma increases, the risk of myopathy development increases.
With the simultaneous use of ethinyl estradiol, norethysterone (norethindron), the concentration of ethinyl estradiol, norethysterone and (norethindron) in the plasma of
blood is slightly increased.
At the same time, the concentration of Atorvastatin in the blood plasma is increased because the inhibitors of the protease are inhibitors of the CYP3A4 isoferment.
Use in pregnancy and breastfeeding
Atorvastatin is shown to be used during pregnancy and lactation (breastfeeding).
It is not known whether or not thorvastatin is released with breast milk. Taking into account the possibility of unwanted phenomena in infants, if necessary, the use of the drug Atoris during lactation should decide whether to stop breastfeeding.
Women of reproductive age should use adequate contraceptive methods during treatment. Atorvastatin can be used in women of reproductive age only if the probability of pregnancy is very low and the patient is informed about the possible risk of treatment for the fetus.
Side Action:
On the side of the nervous system: > 1% - insomnia, dizziness; < 1% - headache, asthenia, malaise, sleepiness, nightmarish dreaming, pastessia, peripheral neuropathy, amnesia, emotional labyllity, ataxia, paralysis Hyperkinesis, migraine, depression, hipesthesia, loss of consciousness.
From the senses: < 1% - ambliopia, tinnitus, conjunctiva dry, acomodation disorder, hemorrhage in the retina of the eye, deafness, glaucoma, parosmia, loss of taste, perversion Sa.
On the side of the cardiovascular system: > 1% - chest pain; < 1% - heartbeat, symptoms of vasodilatsia, ortostatic hypotension, AD rise, flabite, arrhythmia, stenocardia.
On the side of the blood-producing system: < 1% - anemia, lymph adenopathy, thrombocytopenia.
From the respiratory system: > 1% - bronchitis, rinit; < 1% - pneumonia, dyspnoe, acute bronchial asthma, nosebleed.
From the digestive system: > 1% nausea; < 1% - heartburn, constipation or diarrhea, meteorism, gastralgia, abdominal pain, decrease or increase of appetite, dryness in the mouth, bursting, dysphagia, vomiting, glossitis, erotic-ulcer lesions of mucous membranes of the mouth, gastroenteritis, hepatitis, bile colic, helitis, duodenal ulcer, pancreas
Contraindications to use:
Diseases of the liver in the active stage, increased activity of serum transaminosis (more than 3 times as compared to VGN) of the obscure genesis, pregnancy, lactation (breastfeeding), women of reproductive age who do not use reliable means of contraception; Children and adolescents under 18 years of age; increased sensitivity to Atorvastatin.
Special Instructions:
Caution should be applied to alcohol-abusing patients; In the case of anamnesis for liver disease.
Before and during treatment of thorvastatin, especially when there are symptoms of liver damage, it is necessary to control the parameters of liver function. When transaminase levels increase, their activity should be controlled up to normalization. If the ACT or ALT activity is more than 3 times higher than the norm, it is recommended to reduce the dose or cancel the Atorvastatin.
If the symptoms of myopathy appear against the background of treatment, it is necessary to determine the activity of the KFC. If a significant increase in the KFC level is maintained, it is recommended to reduce the dose or cancel the Atorvastatin.
The risk of myopathy during the treatment of thorvasthatin is increased with simultaneous use of cyclosporine, fibros, erythromycin, antifungal drugs Atoris related to azolam and niacin.
There is a possibility of developing the following side reactions, but not in all cases there is a clear connection with the treatment of Atorvastatin: muscle cramps, miositis, myopathy, pastesthesia, peripheral neuropathy, pancreatitis, hepatitis, cholestatic yellowness, anorexia, vomiting, alia itching, rash, impotence, hyperglycemia and hypoglycemia.
Children have limited experience in using thorvastatin in doses up to 80 mg/day.
Aervastatin is used with care in patients with chronic alcoholism.
Application for liver disorders:
Contraindications: liver disease is active.
Application of children
Children have limited experience in using >span class="token_created">in doses up to 80 mg/day.
Nozology (ICD codes)
E78.0
Net Hypercholestery
E78.1
Pure Hyperglyceride
E78.2
Hyperlipid Mixed
